Citius Pharmaceuticals Inc.

About Citius Pharmaceuticals Inc.

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products. Their pipeline includes anti-infectives in oncology, adjunct cancer care, stem cell therapy, and unique prescription products.

Products & Services

LYMPHIR™:A treatment related to oncology, now FDA approved.

Mino-Lok(r):An anti-infective product with a worldwide sales potential of $1.8 billion.

Stem Cell Platform:A platform focused on stem cell therapy.

Halo-Lido:A unique prescription product in development.

Specialties

Critical Care Products Anti-Infectives in Oncology Adjunct Cancer Care Stem Cell Therapy Prescription Products

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Non-dilutive capital via Tax Credit Program T: - FT: Non-dilutive capital via Tax Credit Program	A: 3800000 MR: - FA: $3.8 million FAN: 3800000	D: 2026-02-24 FD: 2026-02-24	1 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 6000000 MR: - FA: 6.0 million FAN: 6000000	D: 2025-10-21 FD: 2025-10-21	-
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 6000000 MR: - FA: 6 million FAN: 6000000	D: 2025-06-12 FD: 2025-06-12	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 6000000 MR: - FA: $6 million FAN: 6000000	D: 2025-06-10 FD: 2025-06-10	1 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2025-04-01 FD: 2025-04-01	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3000000 MR: - FA: 3 million FAN: 3000000	D: 2025-01-08 FD: 2025-01-08	1 investors
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2024-11-18 FD: 2024-11-18	1 investors
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2024-11-15 FD: 2024-11-15	1 investors
9	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: approximately $15 million FAN: 15000000	D: 2024-04-30 FD: 2024-04-30	-
10	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2024-04-26 FD: 2024-04-26	-
11	RT: Non-dilutive Capital T: - FT: Non-dilutive Capital	A: 2400000 MR: - FA: $2.4 million FAN: 2400000	D: 2024-03-07 FD: 2024-03-07	1 investors
12	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2023-05-08 FD: 2023-05-08	1 investors
13	RT: Registered Direct T: - FT: Registered Direct	A: 15000000 MR: - FA: 15 million FAN: 15000000	D: 2023-05-04 FD: 2023-05-04	1 investors

Non-dilutive capital via Tax Credit Program Latest

2026-02-24

$3.8M

1 investor (Pro only)

Registered Direct Offering 2025-10-21

$6.0M

Registered Direct Offering 2025-06-12

$6.0M

View 12 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

I

Issam Raad

Professor and Chair in the Department of Infectious Diseases, Infection Control and Employee Health

M

Mark Rupp

Chief of the Division of Infectious Diseases and Professor in the Department of Internal Medicine, Section of Infectious Diseases at the University of Nebraska Medical Center

L

Leonard A. Mermel

Professor of Medicine, Warren Alpert Medical School of Brown University and Medical Director, Department of Epidemiology & Infection Control, Rhode Island Hospital

J

Joel Rosenblatt

Director of Infectious Disease Technology

L

Leonard Mazur

Co-Founder, CEO and Chairman of the Board of Directors

M

Myron Holubiak

Co-Founder, Executive Vice Chairman

View 21 more team members with Pro

Unlock Full Team Directory

Recent News